South Korea Fines GSK $2.6M Over Pay-For-Delay Deal

Law360, New York (October 24, 2011, 3:11 PM EDT) -- GlaxoSmithKline PLC was hit Monday with a $2.6 million fine by South Korea's Fair Trade Commission over claims that the global pharmaceutical giant struck an improper deal with Seoul-based Dong-A Pharmaceutical Inc. to keep a generic anti-nausea drug off the market.

In a statement released Monday, the South Korean antitrust regulator said the deal was a settlement of patent litigation between the two companies over the anti-nausea drug Zofran, under which Dong-A agreed not to market a generic version of Zofran in return for exclusive rights...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.